[HTML][HTML] Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma

MS Davids, AW Roberts, JF Seymour… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
MS Davids, AW Roberts, JF Seymour, JM Pagel, BS Kahl, WG Wierda, S Puvvada, TJ Kipps
Journal of Clinical Oncology, 2017ncbi.nlm.nih.gov
Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-
Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to
determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally
bioavailable BCL-2 inhibitor.
Abstract
Purpose
B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor.
ncbi.nlm.nih.gov